Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. The actions ...

Novartis has committed another $1.7 billion to its ambition to become a kidney disease leader. The Swiss drugmaker is making the outlay, around half of which is upfront, to buy Regulus ...

Novartis has a lot cooking with new drug launches, and the company is not letting potential U.S. tariffs on pharmaceuticals get in the way of its progress. With recent indication additions, breast ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

April 30 (Reuters) - Novartis (NOVN.S), opens new tab has agreed to buy Regulus Therapeutics (RGLS.O), opens new tab for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health funding crunch, its president of global health told ...

You can reach Jason on Signal at JasonMast.05. Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront. The immediate payout is more ...

Novartis NOVN1.90%increase; green up pointing triangle raised its 2025 outlook after high demand for key drugs drove first-quarter profit and sales above expectations, becoming the first among ...

Novartis NOVN1.25%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS 0.25%increase; green up pointing triangle for a total equity value of up to roughly $1.7 ...

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...